TY - JOUR
T1 - Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged ≤55 years
AU - Lu, Jiachun
AU - Wei, Qingyi
AU - Bondy, Melissa L.
AU - Brewster, Abenaa M.
AU - Bevers, Therese B.
AU - Yu, Tse Kuan
AU - Buchholz, Thomas A.
AU - Meric-Bernstam, Funda
AU - Hunt, Kelly K.
AU - Singletary, S. Eva
AU - Wang, Li E.
N1 - Funding Information:
Acknowledgments This study was supported in part by National Institutes of Health grants CA 108364 (L.E.W.), ES11740 (Q.W.), and CA 16672 (M. D. Anderson Cancer Center). We thank Margaret Lung and Leanel Fairly for their assistance in recruiting the subjects; Luo Wang, Ping Xiong, Yawei Qiao, Kejing Xu, Zhensheng Liu, Zhaozheng Guo, Jianzhong He, and Yinyan Li for their laboratory assistance; and Ann Sutton for scientific editing.
PY - 2008/7
Y1 - 2008/7
N2 - The histone protein family member X (H2AFX) is important in maintaining chromatin structure and genetic stability. Genetic variants in H2AFX may alter protein functions and thus cancer risk. In this case-control study, we genotyped four common single nucleotide polymorphisms (i.e., -1654A > G [rs643788], -1420G > A [rs8551], and -1187T > C [rs7759] in the H2AFX promoter region and 1057C > T [rs7350] in the 3′ untranslated region (UTR)) in 467 patients with sporadic breast cancer and 488 cancer-free controls. All female subjects were non-Hispanic whites aged ≤55 years. We found that significantly increased risk of breast cancer was associated with variant genotypes in the H2AFX promoter: adjusted odds ratio [OR] = 1.80, 95% confidence interval [CI] = 1.38-2.34 for -1654AG/GG; OR = 1.40, 95% CI = 1.07-1.83 for -1420GA/AA; and OR = 1.65, 95% CI = 1.26-2.16 for -1187TC/CC. Furthermore, the number of variant alleles in the promoter haplotypes was associated with increased risks of breast cancer in a dose-response manner (OR = 6.08, 95% CI = 3.25-11.38; OR = 6.83, 95% CI = 3.83-12.18; and OR = 23.61, 95% CI = 3.95-140.99 for one, two, and three variant alleles, respectively) (P trend < 0.0001). Age at onset of breast cancer significantly decreased as the number of variant alleles increased (P trend = 0.024). However, these effects were not observed in the 3′UTR 1057C > T polymorphism. Therefore, we believe that H2AFX promoter polymorphisms may contribute to the etiology of sporadic breast cancer in young non-Hispanic white women. Larger association studies and related functional studies are warranted to confirm these findings.
AB - The histone protein family member X (H2AFX) is important in maintaining chromatin structure and genetic stability. Genetic variants in H2AFX may alter protein functions and thus cancer risk. In this case-control study, we genotyped four common single nucleotide polymorphisms (i.e., -1654A > G [rs643788], -1420G > A [rs8551], and -1187T > C [rs7759] in the H2AFX promoter region and 1057C > T [rs7350] in the 3′ untranslated region (UTR)) in 467 patients with sporadic breast cancer and 488 cancer-free controls. All female subjects were non-Hispanic whites aged ≤55 years. We found that significantly increased risk of breast cancer was associated with variant genotypes in the H2AFX promoter: adjusted odds ratio [OR] = 1.80, 95% confidence interval [CI] = 1.38-2.34 for -1654AG/GG; OR = 1.40, 95% CI = 1.07-1.83 for -1420GA/AA; and OR = 1.65, 95% CI = 1.26-2.16 for -1187TC/CC. Furthermore, the number of variant alleles in the promoter haplotypes was associated with increased risks of breast cancer in a dose-response manner (OR = 6.08, 95% CI = 3.25-11.38; OR = 6.83, 95% CI = 3.83-12.18; and OR = 23.61, 95% CI = 3.95-140.99 for one, two, and three variant alleles, respectively) (P trend < 0.0001). Age at onset of breast cancer significantly decreased as the number of variant alleles increased (P trend = 0.024). However, these effects were not observed in the 3′UTR 1057C > T polymorphism. Therefore, we believe that H2AFX promoter polymorphisms may contribute to the etiology of sporadic breast cancer in young non-Hispanic white women. Larger association studies and related functional studies are warranted to confirm these findings.
KW - Case-control
KW - DNA repair
KW - Double strand break
KW - Genetic susceptibility
KW - Molecular epidemiology
UR - http://www.scopus.com/inward/record.url?scp=44849121622&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=44849121622&partnerID=8YFLogxK
U2 - 10.1007/s10549-007-9717-2
DO - 10.1007/s10549-007-9717-2
M3 - Article
C2 - 17851762
AN - SCOPUS:44849121622
SN - 0167-6806
VL - 110
SP - 357
EP - 366
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 2
ER -